Fate Therapeutics announces completion of public offering of common stock
Fate Therapeutics announced the closing of an underwritten public offering of 6,900,000 shares of its common stock, which included 900,000 shares issued pursuant to the underwriters' option to purchase additional shares, at a public offering price of $5.00 per share. Net proceeds were $32 million. May 27, 2015